EP264/#556 Physician-reported patient involvement in 1l ovarian cancer treatment, including maintenance, in the US and Europe: a real-world chart review analysis (2017–2020)

Abstract

ObjectivesOvarian cancer (OC) treatment options include VEGF inhibitors (VEGFi) and PARP inhibitors (PARPi) as first-line maintenance (1Lm) treatments. There is interest in understanding patient contribution in treatment selection. We describe...